By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long ...

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...

Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data ...

When Hurricane Helene tore through Western North Carolina in September 2024, it didn't just uproot trees and wash out roads.

Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...

W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...

Q4 2025 Management View Richard A. Stewart, President, CEO & Executive Director, emphasized the company's transition from a clinical-stage to a commercially focused enterprise following the NDA ...